{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T20:26:14Z","timestamp":1777753574274,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22271100"],"award-info":[{"award-number":["22271100"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22571095"],"award-info":[{"award-number":["22571095"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109624","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:06:18Z","timestamp":1770998778000},"page":"109624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and evaluation of methoxyquinazoline sulfonamide derivatives as bifunctional molecular targeting tumor related inflammation and anti-EGFR triple-mutation"],"prefix":"10.1016","volume":"173","author":[{"given":"Zhenyou","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longcai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingshu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bioorg.2026.109624_bb0005","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer Progress and priorities: lung Cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109624_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung Cancer 2020: epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109624_bb0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.suc.2021.12.001","article-title":"Lung Cancer: epidemiology and screening","volume":"102","author":"Oliver","year":"2022","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.bioorg.2026.109624_bb0020","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/OTT.S487870","article-title":"Advances in the treatment of rare mutations in non-small cell lung Cancer","volume":"17","author":"Sun","year":"2024","journal-title":"Onco. Targets Ther."},{"issue":"16","key":"10.1016\/j.bioorg.2026.109624_bb0025","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.3748\/wjg.v20.i16.4483","article-title":"Characteristics of gastric cancer in Asia","volume":"20","author":"Rahman","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109624_bb0030","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109624_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.08.009","article-title":"Epidermal growth factor receptor: structure-function informing the design of anticancer therapeutics","volume":"371","author":"Mitchell","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"21","key":"10.1016\/j.bioorg.2026.109624_bb0040","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109624_bb0045","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in Cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes (Basel)"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109624_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.bioorg.2026.109624_bb0055","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0169-5002(03)00136-3","article-title":"Gefitinib (Iressa) trials in non-small cell lung cancer","volume":"41","author":"Johnson","year":"2003","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109624_bb0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/14737140.9.1.17","article-title":"Gefitinib for the treatment of non-small-cell lung cancer","volume":"9","author":"Hida","year":"2009","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.bioorg.2026.109624_bb0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-3-319-91442-8_16","article-title":"Gefitinib","volume":"211","author":"Rawluk","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109624_bb0070","first-page":"S14","article-title":"Erlotinib hydrochloride","volume":"Suppl","author":"Minna","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109624_bb0075","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1517\/14656566.2016.1165206","article-title":"Erlotinib for the treatment of brain metastases in non-small cell lung cancer","volume":"17","author":"Brower","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109624_bb0080","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2217\/fon.14.249","article-title":"Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer","volume":"11","author":"Tan","year":"2015","journal-title":"Future Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109624_bb0085","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4161\/cbt.9.8.11881","article-title":"Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib","volume":"9","author":"Xu","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109624_bb0090","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/1078155220931926","article-title":"Afatinib for the treatment of EGFR mutation-positive NSCLC: a review of clinical findings","volume":"26","author":"Harvey","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109624_bb0095","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"20","key":"10.1016\/j.bioorg.2026.109624_bb0100","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2026.109624_bb0105","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109624_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109624_bb0115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.bioorg.2026.109624_bb0120","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/cancers14081931","article-title":"Acquired mechanisms of resistance to Osimertinib-the next challenge","volume":"14","author":"R\u00edos-Hoyo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.109624_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106057","article-title":"Overcoming C797S mutation: the challenges and prospects of the fourth-generation EGFR-TKIs","volume":"128","author":"Zhao","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109624_bb0130","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2147\/CMAR.S292342","article-title":"Novel resistance mechanisms to Osimertinib analysed by whole-exome sequencing in non-small cell lung Cancer","volume":"13","author":"Wu","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bioorg.2026.109624_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14768","article-title":"Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer","volume":"8","author":"Uchibori","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109624_bb0140","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2481392","article-title":"Fourth-generation EGFR-TKI to overcome C797S mutation: past, present, and future","volume":"40","author":"Zhang","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109624_bb0145","doi-asserted-by":"crossref","DOI":"10.1039\/D4MD00384E","article-title":"Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)","author":"Das","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109624_bb0150","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cas.15229","article-title":"LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo","volume":"113","author":"Liu","year":"2022","journal-title":"Cancer Sci."},{"issue":"14","key":"10.1016\/j.bioorg.2026.109624_bb0155","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung Cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109624_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115015","article-title":"Evaluation of the association of chronic inflammation and cancer: insights and implications","volume":"164","author":"Nigam","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109624_bb0165","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/2159-8290.CD-20-1815","article-title":"Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy","volume":"11","author":"Pelly","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109624_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02243-8","article-title":"Inflammation in cancer: therapeutic opportunities from new insights","volume":"24","author":"Xie","year":"2025","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109624_bb0175","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1172\/JCI97953","article-title":"Role of prostanoids in gastrointestinal cancer","volume":"128","author":"Wang","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109624_bb0180","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1053\/j.gastro.2021.09.059","article-title":"Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal Cancer","volume":"161","author":"Wang","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bioorg.2026.109624_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2026.109624_bb0190","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.biopha.2018.11.004","article-title":"Rosuvastatin attenuates piroxicam-mediated gastric ulceration and hepato-renal toxicity in rats","volume":"110","author":"Abdeen","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109624_bb0195","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1871525716666180913113040","article-title":"Comparison and impact of the short-term use of some non-aspirin NSAIDs on bleeding time of mice","volume":"16","author":"Sukmawan","year":"2018","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109624_bb0200","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00210-019-01806-z","article-title":"Evaluation of histophysiological alterations associated with ketoprofen administration in albino NMRI mice","volume":"393","author":"Paunescu","year":"2020","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109624_bb0205","first-page":"3396","article-title":"Two new quinones and six additional metabolites with potential anti-inflammatory activities from the roots of Juglans mandshurica","volume":"36","author":"Piao","year":"2022","journal-title":"Nat. Prod. Res."},{"issue":"22","key":"10.1016\/j.bioorg.2026.109624_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214108","article-title":"Quinones as an efficient molecular scaffold in the antibacterial\/antifungal or Antitumoral arsenal","volume":"23","author":"Dahlem Junior","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109624_bb0215","article-title":"MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer","volume":"10","author":"Takamori","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109624_bb0220","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1021\/acs.jnatprod.9b00659","article-title":"Discovery of an oleanolic acid\/hederagenin-nitric oxide donor hybrid as an EGFR tyrosine kinase inhibitor for non-small-cell lung cancer","volume":"82","author":"Chen","year":"2019","journal-title":"J. Nat. Prod."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109624_bb0225","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1021\/acs.jmedchem.3c00175","article-title":"Novel aryl sulfonamide derivatives as NLRP3 inflammasome inhibitors for the potential treatment of cancer","volume":"66","author":"Albanese","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109624_bb0230","doi-asserted-by":"crossref","unstructured":"Gao S, Song L, Cheng Y, et al. Discovery of novel sulfonamide substituted indolylarylsulfones as potent HIV-1 inhibitors with better safety profiles. Acta Pharm. Sin. B 2023;13(6):2747\u20132764. doi:https:\/\/doi.org\/10.1016\/j.apsb.2023.01.003.","DOI":"10.1016\/j.apsb.2023.01.003"},{"issue":"11","key":"10.1016\/j.bioorg.2026.109624_bb0235","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"CH7233163 overcomes Osimertinib-resistant EGFR-Del19\/T790M\/C797S mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"29","key":"10.1016\/j.bioorg.2026.109624_bb0240","doi-asserted-by":"crossref","first-page":"22152","DOI":"10.1074\/jbc.M110.119867","article-title":"Structural basis of fatty acid substrate binding to cyclooxygenase-2","volume":"285","author":"Vecchio","year":"2010","journal-title":"J. Biol. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826001604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:03:12Z","timestamp":1777464192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826001604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"alternative-id":["S0045206826001604"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109624","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of methoxyquinazoline sulfonamide derivatives as bifunctional molecular targeting tumor related inflammation and anti-EGFR triple-mutation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109624","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109624"}}